Which T Cell Leaders Are Attending in 2026?
Uniting leaders in Immunology, Preclinical Development, Translational Research, Antibody Engineering, and Immuno-Oncology, the summit will tackle the field's toughest challenges, from optimising tumour selectivity and managing toxicity to enhancing T-cell fitness and improving TCE durability and efficacy.
A*Star
Ability Biotherapeutics
AstraZeneca
Boehringer Ingelheim
Cullinan Therapeutics
Cytospire Therapeutics
Enara Bio
Genmab
GSK
Immatics
Immunocore
iOmx Therapeutics
LabGenius Therapeutics
Molecular Partners
Roche
RoukenBio
Scancell
Servier
Synolo Therapeutics
T-Cypher Bio
Triptych Therapeutics
Veraxa Biotech
Explore the Full Event Guide
- 24+ expert speakers from pioneering biotech and large pharma, including GSK, Cytospire Therapeutics, AstraZeneca, Cullinan Therapeutics, T-Cypher Bio, Immunocore, Synolo Therapeutics, Roche and more
- Gain in-depth data-driven insights into achieving selective targeting of tumour-specific antigens, novel engineering approaches and emerging opportunities for TCEs in oncology and autoimmune diseases
- 5 interactive workshops and panel discussions to solve challenges in resistance, T cell exhaustion and on-target/off-tissue tissue to accelerate more efficacious and potent TCEs towards the clinic
